Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMPV-1 in Healthy Male Subjects
NCT05238558Phase 1Completed
- Sponsor
- Hubro Therapeutics
- Start
- Jan 2022
- Primary completion
- Oct 2022
- Modality
- Peptides, Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of FMPV-1 in colorectal cancer (CRC) (2 cohorts), sponsored by Hubro Therapeutics. Primary endpoints: Delayed Type Hypersensitivity Skin Reactivity Test at 45 days, Proliferative T-cell Responses at 12 months and 1 more. Started Jan 2022; status: completed.
02
Drugs
FMPV-1
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05238558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05238558.